ORGANOGENESIS HOLDINGS INC. Restructuring Charges
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Restructuring Charges of $516.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-02-26
- ORGANOGENESIS HOLDINGS INC. restructuring charges for the quarter ending 2023-12-31 was $1.92M, a 155.73% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. restructuring charges for the quarter ending 2023-09-30 was $96.00K, a 84.29% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. restructuring charges for the quarter ending 2023-06-30 was -$126.00K, a 119.60% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. restructuring charges for the quarter ending 2023-03-31 was $1.91M, a 622.73% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. restructuring charges for fiscal 2025 was $516.00K.
- ORGANOGENESIS HOLDINGS INC. restructuring charges for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- ORGANOGENESIS HOLDINGS INC. restructuring charges for fiscal 2023 was $3.80M, a 67.37% increase from fiscal 2022.
- ORGANOGENESIS HOLDINGS INC. restructuring charges for fiscal 2022 was $2.27M, a 51.79% decline from fiscal 2021.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2025-12-31 | $516.00K 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.01M derived: sum of 2 quarters · filed 2026-02-26 | $1.89M derived: sum of 3 quarters · filed 2026-02-26 | $3.80M 10-K · filed 2026-02-26 |
| 2023-09-30 | $96.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$30.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.88M 10-Q · filed 2024-11-12 | $2.63M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$126.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.78M 10-Q · filed 2024-08-08 | $2.53M derived: sum of 3 quarters · filed 2025-02-27 | $3.14M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.91M 10-Q · filed 2024-05-09 | $2.66M derived: sum of 2 quarters · filed 2025-02-27 | $3.27M derived: sum of 3 quarters · filed 2025-02-27 | $3.91M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $750.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.36M derived: sum of 2 quarters · filed 2025-02-27 | $2.00M derived: sum of 3 quarters · filed 2025-02-27 | $2.27M 10-K · filed 2025-02-27 |
| 2022-09-30 | $611.00K 10-Q · filed 2023-11-09 | $1.25M derived: sum of 2 quarters · filed 2023-11-09 | $1.52M 10-Q · filed 2023-11-09 | $3.35M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $643.00K 10-Q · filed 2023-08-09 | $907.00K 10-Q · filed 2023-08-09 | $2.73M derived: sum of 3 quarters · filed 2024-02-29 | $3.75M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $264.00K 10-Q · filed 2023-05-10 | $2.09M derived: sum of 2 quarters · filed 2024-02-29 | $3.10M derived: sum of 3 quarters · filed 2024-02-29 | $4.04M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $2.84M derived: sum of 2 quarters · filed 2024-02-29 | $3.78M derived: sum of 3 quarters · filed 2024-02-29 | $4.70M 10-K · filed 2024-02-29 |
| 2021-09-30 | $1.01M 10-Q · filed 2022-11-09 | $1.95M derived: sum of 2 quarters · filed 2022-11-09 | $2.88M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $939.00K 10-Q · filed 2022-08-09 | $1.87M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $927.00K 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $618.00K 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |